Panel Post-Mortem: Mela Science's CEO Offers Thoughts On FDA Process
This article was originally published in The Gray Sheet
Executive Summary
Coming out of a tough FDA advisory panel meeting last month for the MelaFind melanoma detection system, Mela Sciences’ CEO Joseph Gulfo says he is satisfied with the outcome but acutely aware of what he sees as FDA's increasing willingness to aggressively challenge a sponsor's data on all fronts.